The capacity of pig gastric mucin-derived glycopeptides to interfere with the binding of cholera toxin (CT) to membrane receptors was studied. Two types of glycopeptide preparations with or without human blood group A antigenic activity were assayed for comparison in a system in which the target for the toxin was rat erythrocyte ghosts. Blood group A-active glycopeptides (A' glycopeptides) were more potent inhibitors for the toxin binding than those lacking group A activity (A-glycopeptides). The mean values of the 50% inhibitory dose revealed that the A' glycopeptide preparations were 6.6-fold-more potent inhibitors than the A-ones (P < 0.001). The inhibitory capacity of the different A' glycopeptide preparations was not directly proportional to the group A antigenic titer. The A' glycopeptides showed a higher capacity than the Aglycopeptides to interact with the toxin as revealed by CT-glycopeptide complex formation, which could be detected by Sephacryl S-400 chromatography. This result suggests that glycopeptide inhibition of CT binding to the erythrocyte ghosts is mediated by a competition between the GM1 receptors and the glycopeptides for the toxin. The differential effect between both types of glycoconjugates was independent of the way of measuring the amount of glycopeptides used (dry weight, carbohydrate or protein content). The existence in the gastrointestinal tract of mucins not carrying or carrying different ABO blood group determinants, which could behave as more or less potent inhibitors of CT binding to membrane receptors, may help to explain the relationship between ABO blood groups and severity of cholera.
An association has been observed between the ABO blood group system and the susceptibility of a person to develop diarrhea caused by Vibrio cholerae infection. Individuals with blood group 0 have a higher risk to be affected by the disease than persons with other blood groups (1, 5, 6, 13, 18) . The underlying mechanism(s) of this genetically related predisposition is at present unknown even though attempts to elucidate it have been made (13) . However, several hypotheses have been proposed which consider some relationships between particular properties of the vibrio itself or the enterotoxin it secretes and characteristics of the host organism, which in turn are associated with the ABO group system (2) (3) (4) 6) . In connection with this, we recently reported the presence in pig intestinal mucosa of a neutral fucolipid which binds cholera toxin (CT) and is recognized by anti-human blood group A antiserum. This glycosphingolipid was detected in tissue from pigs carrying blood group A-active substances (A' pigs) but not in those lacking these substances (A-pigs) (2) . On this basis, our working hypothesis is that individuals with blood group 0 show a predisposition for cholera due to a deficit of some compounds with antigenic properties of blood group A or B or both (mucins?). These compounds would be able to interact with CT, therefore disturbing its binding to ganglioside GM1, which is accepted to be the natural toxin membrane receptor (for a review, see reference 23) . Blood group determinants are present in high proportions in the gastrointestinal tract of several animal species as glycosphingolipids and glycoproteins; the latter occur as mucins in the tissue fluids of secretor individuals (12, 22) . The present study was under-* Corresponding author.
taken to evaluate the capacity of glycopeptides derived from pig gastric mucins to interfere with the binding of CT to membrane receptors. For this purpose, glycopeptides with (A' glycopeptides) or without (A-glycopeptides) human blood group A antigenic activity were used for comparison.
MATERIALS AND METHODS Materials. CT produced by classical V. cholerae 569B Inaba, Ulex europaeus I lectin, bovine serum albumin (BSA), blue dextran, and Sephacryl S-400 were from Sigma Chemical Co. (St. Louis, Mo.). Pronase was obtained from Calbiochem-Behring Diagnostics (La Jolla, Calif.). Bio-Gel P-100 and Bio-Gel A-50 (50/100 mesh) were from Bio-Rad Laboratories (Richmond, Calif.). Na'251, carrier free (17 mCi/pLg), was from Radiochemical Centre (Amersham, United Kingdom). Human anti-A serum was from Ortho Diagnostic Systems, Inc. (Raritan, N.J.).
Mucin glycopeptide preparations. Gastric mucus samples from individual pigs were collected by instillation (30) (approximately 1 h) of dissected pig stomachs with 2 M NaCl-10 mM sodium phosphate buffer (pH 7.4) at 4°C. The instillate was dialyzed against distilled water and lyophilized. Gastric mucus (1 g) was subjected to exhaustive lipid extraction with 100 ml of the following solvent mixtures (29) 25 ,ul of a twofold step dilution of mucin glycopeptides was incubated for 30 min with 8 units of antiserum or lectin before the addition of the erythrocytes. The blood group titer of mucin glycopeptides was determined as the minimal amount of glycopeptides contained in the final volume of the system (75 ,lI) able to cause hemagglutination inhibition.
'251-CT binding assays. For binding of CT, essentially the method described by Sahyoun et al. (26) was used. Rat erythrocyte ghosts were prepared by hypotonic lysis by the method of Hanahan and Ekholm (14) . 125I-CT (1.5 to 3.0 nM) was incubated for 20 min at room temperature with rat erythrocyte ghosts and 0.2 ml of 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (pH 7.4) containing 2 mM MgCl2, 130 mM NaCl, and 5 mM KCI. At this incubation time, binding equilibrium has been reached. To separate the bound from the free toxin, we added 2 ml of ice-cold incubation buffer and the tubes were immediately centrifuged at 20,000 x g for 5 min. The pellet was washed once with 2 ml of the same buffer and counted in an LS 7000 liquid scintillation counter (Beckman Instruments, Inc., Fullerton, Calif.).
Binding of 125I-CT with increasing amounts of rat erythrocyte ghosts was linear between 0.2 and 2 to 3 ,ug of membrane protein; in an excess of membrane (3 to 10 jig of protein), a plateau was reached, and in this protein range, the amount of bound counts per minute (cpm) was approximately 50% of the total radioactivity added. Nonspecifically bound toxin was determined at 2 to 3 ,ug of membrane protein by pretreating the erythrocyte preparation with 60 To assay the ability of the mucin glycopeptides to inhibit the binding of 125I-CT in the erythrocyte ghost system, we preincubated the desired amount of glycopeptides with 125I-CT for 60 min at room temperature before adding the erythrocyte membrane preparation (usually 2 ,ug of protein). The difference between the cpm of 125I-CT bound to the membrane in the absence and in the presence of glycopeptides was expressed as the percentage of binding inhibition. The precipitated cpm of controls (in which mucin glycopeptides were incubated with 1251-CT in the same conditions except that no erythrocyte ghosts were added) were subtracted from the cpm measured in the complete system. The cpm of this control were approximately 5 to 15% of the binding of the toxin to the ghosts, and this value was similar to that obtained when 125I-CT was incubated in the absence of ghosts and glycopeptides.
Chromatography on Sephacryl S-400. 125I-CT (2.0 nM) was applied to a Sephacryl S-400 column either alone or after incubation for 60 min at room temperature with mucin glycopeptides (an amount equivalent to 2.8 optical density units after the PAS reaction) in 0.2 ml of 20 mM HEPES buffer (pH 7.4) containing 130 mM NaCl, 5 mM KCl, and 2 mM MgCl2. The column (0.9 by 13 cm) was equilibrated in and eluted with the incubation buffer containing 0.1% BSA. The radioactivity of each fraction (0.75 ml) was determined in a Gamma 4000 counter (Beckman Instruments, Inc., Irvine, Calif. tides to inhibit binding of '251-CT to membrane receptors. To gain some insights into the physiopathological mechanism(s) involved in the association between the ABO blood groups and cholera, we evaluated the capacity of A' and A-mucin glycopeptides to interfere with the binding of CT to membrane receptors.
In a system in which rat erythrocyte ghosts were used as the '25I-CT target, the A' glycopeptides were more potent inhibitors of the toxin binding than the A-counterparts. A general feature of mucus glycoproteins is the presence of a protein core containing heavily glycosylated regions which are protected from proteolytic attack and nonglycosylated regions susceptible to proteolytic digestion. The oligosaccharide chains show considerable variation in length, composition, and sequence of monosaccharides (24) . As a consequence, the mucin glycopeptide preparations are heterogeneous; therefore, the capacity of the glycopeptides to inhibit the CT binding was compared on the basis of dry weight or carbohydrate or protein content. Figure 1 shows the percent inhibition of CT binding caused by different amounts of the individual mucin glycopeptide preparations. In general, the A' and the A-glycopeptides could be divided into two populations with respect to their inhibitory capacity, especially when the mucin glycopeptides were quantified by the carbohydrate content by using the anthrone (Fig. 1) or PAS (data not shown) reaction. When the glycopeptides were measured by dry weight or protein content (data not shown), only one A' preparation (glycopeptide 4) overlapped with the A-population. When the group A antigenic titer (Table 1) was compared with the capacity of the individual glycopeptide preparations to inhibit CT binding ( Fig. 1) , no direct correlation was observed. For instance, glycopeptide 8, which showed the highest group A titer, is one of the less potent inhibitors of the CT binding. Conversely, glycopeptide 7, which has a relatively low group A titer, showed a considerable capacity to inhibit binding. This lack of correlation was not surprising since not all pig intestinal blood group A-active glycosphingolipids interact with CT (2). The lack of strict correlation between the group A antigenic titer and the inhibitory capacity of the A' glycopeptides together with the fact that A-glycopeptides also show some ability to inhibit the toxin binding indicate that the A antigenic determinant is not the only chemical structure implicated in this inhibitory effect. The values of inhibition of CT binding obtained with individual glycopeptide preparations were statistically analyzed as grouped samples. Differences between means of the inhibitory effect of the A' and A-mucin glycopeptide populations at the concentrations considered were statistically significant independently of the way of measuring the amount of glycopeptides. All the P values were lower than 0.005. Figure 2 shows the results obtained when the mucin glycopeptides were expressed as dry weight or protein content. Similar results were found on the basis of glycopeptide carbohydrate content in the range of 0.6 to 1. Characterization of inhibitory effect of mucin glycopeptides on CT binding to erythrocyte ghosts. With respect to the nature of the inhibition process, at least two possibilities can be considered. One possibility is that the glycopeptides interact with CT, sequestering it from the environment, thus preventing its binding to the membrane; the other is that the glycopeptides interfere with CT binding by acting on the membrane receptors. Evidence obtained by kinetic and CT-glycopeptide interaction experiments supports the first possibility. In the erythrocyte system, an increasing percentage of CT inhibition was observed depending on the incubation time of CT with the glycopeptides (from 0 to 60 min) before the ghosts were added, whereas no time-dependent inhibition was noted when glycopeptides were incubated with the erythrocyte membranes (from 0 to 30 min) before the addition of the toxin (data not shown). CT-glycopeptide interaction was studied by gel filtration chromatography. Different elution profiles on a Sephacryl S-400 column for the labeled toxin alone or after its incubation with A' glycopeptides were observed (Fig. 3) . In the last case, the shoulder in the radioactive peak showed a fair coincidence with the elution profile of the glycopeptides, implying the presence of a rather stable CT-glycopeptide complex. In this system, a preferential interaction of CT with A' rather than A-glycopeptides was clearly observed, suggesting that the glycopeptide inhibitory property in the erythrocyte system can be due to this differing capacity of the glycopeptides to interact with the toxin. The ratio of CT-A' glycopeptide complex/free toxin did not change when the incubation time of the toxin with the glycopeptides was increased (up to 3 h) or when the amount of the glycoconjugates was doubled, indicating that no free active toxin remains in the system. These results are consistent with studies of CT binding to GM,-coated polystyrene plates (27) (data not shown) or to erythrocyte ghosts (see Materials and Methods) indicating that approximately 30% of our labeled toxin preparation is inactive. Partial inactivation of 251I-CT has been previously described (7) .
Even if the present results cannot be extrapolated to an in vivo situation regarding an association between ABO blood groups and diarrheal diseases caused by enterotoxigenic bacteria, some speculations can be made. CT and the heat-labile toxins (LT) produced by Escherichia coli which colonize either human (LTh) or pig (LTp) intestine have several structural, functional, and immunological properties in common (9, 11, 23, 33) . Also, as in cholera, a similar relationship between ABO blood groups and the occurrence of diarrhea after ingestion of LT-producing E. coli has been recently described in studies with volunteers (3) . If the ABO blood group association also applies to LTp, our results could have a practical interest, since it will be possible to breed pigs to get progeny with a determined ABO-related phenotype which, in turn, will influence the severity of an eventual diarrhea caused by infection with enterotoxigenic E. coli. If blood group-active mucins play an important role in the predisposition for diarrhea caused by cholera-related enterotoxins, in addition to the particular blood group, the secretor status of an individual must be considered. A prevalence of nonsecretors among patients with cholera was found in a clinical survey (4), while no difference was observed in another study (13) . However, in none of these reports was the blood group of the individuals taken into account simultaneously with the secretor character, and this may be the reason for the dissimilar results. If our hypothesis considering a differential capacity of mucins to inhibit the toxin-receptor interaction depending on their ABO blood group determinants is proved to operate in humans, no ABO-related differences should be expected among nonsecretor patients.
CT is able to induce intestinal mucin secretion, which is believed to have a protective role during vibrio infection by constituting a physical barrier preventing the bacterium and/or the exotoxin from reaching the mucosal cells (10, 17, 28) . This phenomenon probably occurs in human beings independently of the ABO blood groups. The present results suggest that the hypersecretion of mucus induced by the toxin represents an additional and more selective mechanism of protection depending on the particular ABO blood group determinant secreted.
